Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.22B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$504M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$335M |
| 4 |
Bank of America
BAC
|
+$324M |
| 5 |
TSMC
TSM
|
+$297M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.62B |
| 2 |
Meta Platforms (Facebook)
META
|
+$471M |
| 3 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$396M |
| 4 |
NVIDIA
NVDA
|
+$391M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$275M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.25% |
| 2 | Technology | 2.31% |
| 3 | Consumer Discretionary | 1.61% |
| 4 | Financials | 1.35% |
| 5 | Healthcare | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMRN
11451
Immuron
IMRN
$9.44M
| $72.5K | ﹤0.01% |
39,404
-454
| -1% | -$916 |
|
|
KLRS
11452
CALL
Kalaris Therapeutics
KLRS
$97.6M
| $72.5K | ﹤0.01% |
+800
| New | +$102K |
|
|
RCS
11453
PIMCO Strategic Income Fund
RCS
$249M
| $71.9K | ﹤0.01% |
+13,511
| New | +$74.8K |
|
11454
PUT
Wipro
WIT
$17.8B
| $71.8K | ﹤0.01% |
+32,000
| New | +$76.1K |
|
|
DPRO
11455
CALL
Draganfly
DPRO
$162M
| $71.8K | ﹤0.01% |
+2,244
| New | +$92.5K |
|
11456
Amneal Pharmaceuticals
AMRX
$6.27B
| $71.8K | ﹤0.01% |
51,655
+14,267
| +38% | +$28.4K |
|
|
BON
11457
Bon Natural Life
BON
$9.27M
| $71.8K | ﹤0.01% |
+202
| New | +$77K |
|
|
AUTL
11458
Autolus Therapeutics
AUTL
$628M
| $71.7K | ﹤0.01% |
38,947
+18,744
| +93% | +$36.6K |
|
|
GTHX
11459
PUT
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $71.6K | ﹤0.01% |
26,700
-10,900
| -29% | -$52.4K |
|
|
QIPT
11460
PUT
DELISTED
Quipt Home Medical
QIPT
| $71.5K | ﹤0.01% |
+10,200
| New | +$62.8K |
|
11461
PUT
BioAtla
BCAB
$5.23M
| $71.3K | ﹤0.01% |
532
-900
| -63% | -$162K |
|
11462
Intellinetics
INLX
$23.6M
| $71.1K | ﹤0.01% |
+17,691
| New | +$75.4K |
|
11463
CALL
Fossil Group
FOSL
$318M
| $71K | ﹤0.01% |
22,200
-19,300
| -47% | -$86.7K |
|
11464
PUT
Alaunos Therapeutics
TCRT
$4.22M
| $71K | ﹤0.01% |
751
-399
| -35% | -$38K |
|
|
SOLO
11465
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
| $71K | ﹤0.01% |
136,654
+79,500
| +139% | +$64.3K |
|
|
AGFS
11466
PUT
DELISTED
AgroFresh Solutions Inc
AGFS
| $70.5K | ﹤0.01% |
23,500
-10,000
| -30% | -$29.8K |
|
11467
CALL
Hyperfine
HYPR
$89.7M
| $70.4K | ﹤0.01% |
+48,900
| New | +$59.8K |
|
|
QCLS
11468
PUT
Q/C Technologies Inc
QCLS
$19.4M
| $70.3K | ﹤0.01% |
+14
| New | +$78.1K |
|
11469
PUT
Relmada Therapeutics
RLMD
$482M
| $70.3K | ﹤0.01% |
31,100
+10,800
| +53% | +$37.2K |
|
11470
CALL
Zevia
ZVIA
$102M
| $70.1K | ﹤0.01% |
18,200
-8,200
| -31% | -$33.1K |
|
11471
CALL
AXT Inc
AXTI
$4.39B
| $69.7K | ﹤0.01% |
17,500
-2,800
| -14% | -$13.6K |
|
11472
MediciNova
MNOV
$69.9M
| $69.5K | ﹤0.01% |
32,180
-32,176
| -50% | -$73.7K |
|
11473
PUT
Capricor Therapeutics
CAPR
$585M
| $69.2K | ﹤0.01% |
16,400
-95,600
| -85% | -$412K |
|
|
SEEL
11474
CALL
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $69.2K | ﹤0.01% |
26
-14
| -35% | -$41K |
|
11475
GeneDx Holdings
WGS
$2.66B
| $69.1K | ﹤0.01% |
5,737
+3,621
| +171% | +$48.3K |
|
Similar funds
Jeff Yass's Q1 2023 Portfolio in Review
As of Q1 2023, Jeff Yass held 14,310 positions worth $470B, up 19% from $395B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jeff Yass's Q1 2023 filing shows 2,075 new, 5,756 increased, 4,471 reduced and 1,856 closed positions. Its largest new stake was Schwab US Aggregate Bond ETF: 2,949,950 shares worth $69.2M. The largest sale was Tesla, an estimated $1.62B.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 91% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q1 2023 buy was Schwab US Aggregate Bond ETF: 2,949,950 shares worth $69.2M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2023, an estimated $1.22B increase.
- Jeff Yass's biggest Q1 2023 reduction was Tesla, cutting an estimated $1.62B.
- Jeff Yass fully exited NextEra Energy, Inc. 5.279% Corporate Units in Q1 2023, selling an estimated $61.5M.
- Jeff Yass's ten largest holdings make up 30% of its $470B portfolio in Q1 2023.
- Jeff Yass opened 2,075 new positions and closed 1,856 in Q1 2023.
- Jeff Yass's portfolio value rose 19% quarter-over-quarter to $470B.
Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.